Unternehmensantwort
Wyeth (part of Pfizer) hat nicht geantwortet auf
Oxfam report says top drug companies focusing on patents, not the poor
Zeitleiste
-
Response by Sanofi-Aventis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
Verfügbare Sprachen: English -
Wyeth (part of Pfizer) did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
Verfügbare Sprachen: English -
Response by Johnson & Johnson: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
Verfügbare Sprachen: English -
Response by Abbott Laboratories: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
Verfügbare Sprachen: English -
Response by Merck: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices"
Verfügbare Sprachen: English -
Response by Novartis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
Verfügbare Sprachen: English -
Response by AstraZeneca: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
Verfügbare Sprachen: English -
Eli Lilly did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
Verfügbare Sprachen: English -
Response by Pfizer: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
Verfügbare Sprachen: English -
Bristol-Myers Squibb did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
Verfügbare Sprachen: English -
Roche did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
Verfügbare Sprachen: English -
Oxfam report "Investing for Life": Company responses
Verfügbare Sprachen: English -
La industria farmacéutica socava su futuro mientras impide el acceso de millones de personas a medicamentos básicos
Verfügbare Sprachen: español -
Oxfam says top drug companies focusing on patents, not poor
Verfügbare Sprachen: English -
L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments
Verfügbare Sprachen: français -
Response by GlaxoSmithKline: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".
Verfügbare Sprachen: English -
[PDF] Investing for life - Meeting poor people’s needs for access to medicines through responsible business practices
Verfügbare Sprachen: English
Vollständige Story anzeigen